Prospective follow-up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: Comparative and overall neonatal outcome

Human Reproduction

Volumn 27, Issue 7, 2012, Pages 2177-2185

  Bonduelle, Maryse ^a   Mannaerts, Bernadette ^b   Leader, Arthur ^c   Bergh, Christina ^d   Passier, Dorrie ^b   Devroey, Paul ^e  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b MSD   (Netherlands)

^c UNIVERSITY OF OTTAWA   (Canada)

^d SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^e CENTRE FOR REPRODUCTIVE MEDICINE   (Belgium)

Author keywords

assisted reproduction techniques; congenital malformations; controlled ovarian stimulation; corifollitropin alfa; GnRH antagonist

Indexed keywords

CORIFOLLITROPIN ALFA; RECOMBINANT FOLLITROPIN;

ARTICLE; CLEFT PALATE; CONGENITAL HYDROCEPHALUS; CONGENITAL MALFORMATION; CONTROLLED OVARY STIMULATION; CYSTIC LYMPHANGIOMA; EBSTEIN ANOMALY; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; FETUS; FETUS HYDROPS; FOLLOW UP; HUMAN; INFERTILITY THERAPY; KIDNEY DYSPLASIA; KIDNEY MALFORMATION; LABOR; LIVE BIRTH; LUNG MALFORMATION; MAJOR CLINICAL STUDY; NEWBORN DEATH; PREGNANCY; PREGNANCY OUTCOME; PREMATURITY; PROSPECTIVE STUDY; SKULL MALFORMATION; SOLITARY KIDNEY; STILLBIRTH; TRISOMY 18; TRISOMY 21;

EID: 84863570603     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/des156     Document Type: Article

References (30)

1. Anthony S, Buitendijk SE, Dorrepaal CA, Lindner K, Braat DDM, den Ouden AL. Congenital malformations in 4224 children conceived after IVF. Hum Reprod 2002;8:2089-2095.
2. Balen AH, Mulders AG, Fauser BC, Schoot BC, Renier MA, Devroey P, Struijs MJ, Mannaerts BM. Pharmacodynamics of a single low dose of long-acting recombinant follicle-stimulating hormone (FSH-carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization group II anovulatory infertility. J Clin Endocrinol Metab 2004;89:6297-6304. (Pubitemid 39628449)
3. Boerrigter PJ, de Bie JJ, Mannaerts BM, van Leeuwen BP, Passier-Timmermans DP. Obstetrical and neonatal outcome after controlled ovarian stimulation for IVF using the GnRH antagonist ganirelix. Hum Reprod 2002;17:2027-2034.
4. Bonduelle M, Liebaers I, Deketelaere V, Derde MP, Camus M, Devroey P, Van Steirteghem A. Neonatal data on a cohort of 2889 infants born after ICSI (1991-1999) and of 2995 infants born after IVF (1983-1999). Hum Reprod 2002;17:671-694. (Pubitemid 34232438)
5. Bonduelle M, Oberyé J, Mannaerts B, Devroey P. Large prospective, pregnancy and infant follow-up trial assures the health of 1000 fetuses conceived after treatment with the GnRH antagonist ganirelix during controlled ovarian stimulation. Hum Reprod 2010;25:1433-1440.
6. Chang HJ, Lee JR, Jee BC, Suh CS, Kim SH. Impact of blastocyst transfer on offspring sex ratio and the monozygotic twinning rate: a systematic review and meta-analysis. Fertil Steril 2009;91:2381-2390.
7. Corifollitropin Alfa Ensure Study Group. Corifollitropin alfa for controlled ovarian stimulation in lVF: a randomized trial in lower-body-weight women. Reprod Biomed Online 2010;21:66-76.
8. Devroey P, Fauser BC, Platteau P, Beckers NG, Dhont M, Mannaerts BM. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab 2004;89:2062-2070. (Pubitemid 38647174)
9. Devroey P, Boostanfar R, Koper NP, Mannaerts BMJL, IJzerman-Boon PC, Fauser BCJM; on behalf of the ENGAGE Investigators. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 2009;24:3063-3072.
10. Ericson A, Källén B. Congenital malformations in infants born after IVF: a population-based study. Hum Reprod 2001;16:504-509. (Pubitemid 32218802)
11. Fatemi HM, Oberye J, Popovic-Todorovic B, Witjes H, Mannaerts B, Devroey P. Corifollitropin alfa in a long GnRH agonist protocol: proof of concept trial. Fertil Steril 2010;94:1922-1924.
12. Fauser BCJM, Mannaerts BMJL, Devroey P, Leader A, Boime I, Baird DT. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Hum Reprod Update 2009;15:309-321.
13. Hansen M, Kurinczuk JJ, Bower C, Webb S. The risk of major birth defects after intracytoplasmic sperm injection and in vitro fertilization. N Engl J Med. 2002;346:725-730. (Pubitemid 34983992)
14. Hansen M, Bower C, Milne E, de Klerk N, Kurinczuk J. Assisted reproductive technologies and the risk of birth defects-A systematic review. Hum Reprod 2005;20:328-338. (Pubitemid 40277599)
15. Knopman J, Krey LC, Lee J, Fino ME, Novetsky AP, Noyes N. Monozygotic twinning: an eight-year experience at a large IVF center. Fertil Steril 2010; 94:502-510.
16. Kurinczuk JJ. Safety issues in assisted reproduction technology. From theory to reality-just what are the data telling us about ICSI offspring health and future fertility and should we be concerned? Hum Reprod 2003;18:925-931. (Pubitemid 36592029)
17. Ledger WL, Fauser BCJM, Devroey P, Zandvliet AS, Mannaerts BMJL. Corifollitropin alfa doses based on body weight: clinical overview of drug exposure and ovarian response. Reprod Biomed Online 2011;23:150-159.
18. Leppig KA, Werler MM, Cann CI, Cook CA, Holmes LB. Predictive value of minor anomalies. I. Association with major malformations. J Pediatrics 1987;110:531-537. (Pubitemid 17049037)
19. Norman RJ, Zegers-Hochschild F, Salle BS, Elbers J, Heijnen E, Marintcheva-Petrova M, Mannaerts B. Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity. Hum Reprod 2011;26:2200-2208.
20. Nygren KG, Finnström O, Källen B, Olausson PO. Population-based Swedish studies of outcomes after in vitro fertilisation. Acta Obstet Gynecol Scand 2007;86:774-782. (Pubitemid 47035838)
21. Reefhuis J, Honein MA, Schieve LA, Correa A, Hobbs CA, Rasmussen SA. And the National Birth Defects Prevention Study. Assisted reproductive technology and major structural birth defects in the United States. Hum Reprod 2009;24:360-366.
22. Rimm AA, Katayama AC, Diaz M, Katayama KP. A meta-analysis of controlled studies comparing major malformation rates in IVF and ICSI infants with naturally conceived children. J Assist Reprod Genet 2004;21:437-443. (Pubitemid 40202714)
23. Simpson JL. Registration of congenital anomalies in ART populations: pitfalls. Hum Reprod 1996;11(Suppl. 4):81-88.
24. Sterrenburg MD, Heijnen EM, Macklon NS, Mannaerts B, Fauser BC. Corifollitropin alfa followed by a low dose of rFSH or hCG to induce monofollicular growth in women with WHO group II anovulatory infertility; a pilot study. Fertil Steril 2009;92:S86.
25. Sutcliffe AG, Ludwig M. Outcome of assisted reproduction. Lancet 2007; 370:351-359. (Pubitemid 47094972)
26. Tararbit K, Houyel L, Bonnet D, De Vigan C, Lelong N, Goffinet F, Khoshnood B. Risk of congenital heart defects associated with assisted reproductive technologies: a population-based evaluation. Eur Heart J 2011;32:500-508.
27. The Corifollitropin Alfa Dose-Finding Study Group. A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Hum Reprod 2008;23:2484-2492.
28. Verbost P, Sloot WN, Rose UM, de Leeuw R, Hanssen RG, Verheijden GF. Pharmacologic profiling of corifollitropin alfa, the first developed sustained follicle stimulant. Eur J Pharmacol 2011;651:227-233.
29. Wen SW, Leader A, White RR, Léveillé MC, Wilkie V, Zhou J, Walker MC. A comprehensive assessment of outcomes in pregnancies conceived by in vitro fertilization/intracytoplasmic sperm injection. Eur J Obstet Gynecol Reprod Biol 2010;150:160-165.
30. Zhu JL, Basso O, Obel C, Bille C, Olsen J. Infertility, infertility treatment, and congenital malformations: Danish national birth cohort. BMJ 2006; 20:3173-3177.